Microba Life Sciences Limited (AU:MAP) has released an update.
Microba Life Sciences Limited has reported a record increase in sales and revenue for Q4 FY24, with strong performance in its personal testing and supplements, particularly the gastrointestinal disorder test MetaXplore in Australia. The company witnessed a successful first six months for Invivo Clinical in the UK and completed a groundbreaking Autoimmune therapeutic discovery program. With substantial cash reserves and advancements in their therapeutic development programs, Microba is actively preparing for Phase 2 clinical trials and looks forward to continued growth.
For further insights into AU:MAP stock, check out TipRanks’ Stock Analysis page.
